Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Total Non-Current Liabilities: 2020-2024

Historic Total Non-Current Liabilities for Puma Biotechnology (PBYI) over the last 4 years, with Dec 2024 value amounting to $121.1 million.

  • Puma Biotechnology's Total Non-Current Liabilities fell 31.58% to $121.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $121.1 million, marking a year-over-year decrease of 31.58%. This contributed to the annual value of $121.1 million for FY2024, which is 31.58% down from last year.
  • Latest data reveals that Puma Biotechnology reported Total Non-Current Liabilities of $121.1 million as of Q4 2024, which was down 19.01% from $149.5 million recorded in Q3 2024.
  • In the past 5 years, Puma Biotechnology's Total Non-Current Liabilities registered a high of $241.1 million during Q1 2021, and its lowest value of $121.1 million during Q4 2024.
  • For the 3-year period, Puma Biotechnology's Total Non-Current Liabilities averaged around $165.5 million, with its median value being $163.0 million (2023).
  • Per our database at Business Quant, Puma Biotechnology's Total Non-Current Liabilities increased by 1.74% in 2021 and then crashed by 31.58% in 2024.
  • Over the past 5 years, Puma Biotechnology's Total Non-Current Liabilities (Quarterly) stood at $224.2 million in 2020, then climbed by 1.74% to $228.1 million in 2021, then fell by 15.37% to $193.1 million in 2022, then declined by 8.34% to $177.0 million in 2023, then tumbled by 31.58% to $121.1 million in 2024.
  • Its last three reported values are $121.1 million in Q4 2024, $149.5 million for Q3 2024, and $156.4 million during Q2 2024.